Cutaneous T-Cell Lymphomas in Special Populations
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 30 April 2026 | Viewed by 10
Special Issue Editors
Interests: mature NK/T cell lymphoma; biological therapies; cellular therapies; predictive and prognostic biomarkers; immunodeficiency associated lymphomas
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Despite recent therapeutic advances, cutaneous T-cell lymphoma (CTCL) remains an incurable malignancy. Treatment can be difficult due to variability in patient response to therapy and the lack of reliable prognostic biomarkers. Additionally, CTCL and other cutaneous lymphoproliferative diseases can be diagnostically challenging due to their diverse clinical presentations. Management of CTCL patients therefore requires careful consideration of how their disease may be affected by age, geography, cancer history, and other clinical factors.
In this Special Issue, we present an overview of CTCL diagnosis, staging, treatment, and translational research in special populations, including pediatric patients, individuals from Latin American descent, post-hematopoietic stem cell transplant recipients, patients with secondary malignancies, and individuals with skin of color. The topics reviewed are a summary of those presented during the 2025 United States Cutaneous Lymphoma Consortium (USCLC) Workshop. We appreciate the contributions of experts across multiple fields and welcome partnership in caring for this unique patient population.
Dr. Stefan K. Barta
Dr. Caroline Myers
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cutaneous T-cell lymphoma
- adult T-cell leukemia/lymphoma
- lymphoproliferative disorder
- hematopoietic stem cell transplant
- secondary malignancy
- pediatric lymphoma
- skin of color
- health care disparities
- translational research
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
